Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial
Danyal Ladha, Ranjeeta Mallick, Tzu‐Fei Wang, Lucia Caiano, Philip S. Wells, Marc Carrier
Topics & Concepts
Post-hoc analysisApixabanMedicinePost hocOncologyPrimary preventionSafety profileInternal medicineClinical trialSecondary preventionIntensive care medicineAdverse effectWarfarinRivaroxabanAtrial fibrillationDiseaseVenous Thromboembolism Diagnosis and ManagementHepatocellular Carcinoma Treatment and PrognosisInflammatory Biomarkers in Disease Prognosis